to view your mail
U.S. Markets closed
Recro Pharma, Inc. (REPH)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 1:00PM EST
786 reactions on $REPH conversation
Sign in to post a message.
What has caused the fairly steady 3 year drop from $70s to <$1 for REPH?
Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products
Long, Proven Track Record of Successful Commercial Drug Product Manufacturing, Serving Both Large Pharma and Emerging Companies
As a company that manufactures drugs, why wouldn’t a major bio Pharma ship some manufacturing over to companies like REPH under “Operation Warp Speed”? Or, why would they not offload some other work while they are manufacturing the Covid vaccine??
No mention of new CEO. Not even asked by the analysts...to regain trust this will take years to come back to 10s. Liquidity risks and cash flow contraints are still there...
New CEO is going to change the momentum. Hence, the financing part gives some time to recvoer and eliminate liquidation risks in the near term. it is still there however if no turnaround is there in H1 2021!
So management is having REPH's and BXRX's earnings call at the same time. I ask you, how Mickey Mouse can you get? The only thing that will salvage this earnings call will be that Gerri announces that she, her sister, her brother, her brother in-law, her aunt, her niece, her neighbor, and her house cleaner are all stepping down from their various roles in the company and returning to their consulting positions at Malvern Consulting.
Only thing I want to hear next week is that they have finally found a new CEO. That’s the only thing that will move this stock.
After the tax selling in Dec, assume there will be. Let's hope this runs up to 4 to 5 range by next Q report. My wishful thinking.
$2 is sticking at least... lets see
Just sold 110 shares at $1.5. Took a small hit this time. This stock has not been good to me. Took a huge hit from a previous transaction a few weeks ago. GLTA. Don't know what to advise you good folks out there.
great outlook in call...finally!
Really torn here to just sell all my shares and take a 60% loss or gamble loosing it all on the stock tanking even more from Monday’s likely disastrous ER. The only thing that keeps me hanging on is for Gerri and her incompetent management to leave and go destroy another company.
Anyone have a greater insight? They appeared to have the cash and loan so they seemed to be able to ride out the pandemic with some new contracts ??? Just puzzled how it keeps getting beat up. Just wondering if this is collateral damage due to BXRX?
Companies like Recro Pharma should be banned to be traded on public stock market. It's univestable. It's only purpose of existence is to make sure CEO and CFO are paid way above their capability deserve, and maybe the jobs for its employee.
Wild Bill from Outta Town
We the shareholders need to get together to start a class action lawsuit to get current management removed! They have run this company straight into the ground!! Imagine getting 2 large pay checks for driving the share price of both companies down by 80% in less than 1 year???
Guy Who Trades
Gerri's gonna hang onto this cash cow from her fingernails until they are auctioning off the office furniture. She can't rely on Baudax to stick around, what with the massive cash burn and zero sales growth and next to zero revenue last quarter.
Yahoo rating as “strong buy” why its going down n down so bad?
have we found a bottom? perhaps
Why REPH should go down after better Q3 results ? What I am missing
I guess every day is going to be a new 52-week low until after earnings
Hawaii seeks to be seen as a remote workplace with a view
Trump says he will leave White House if Biden wins electoral college
Yahoo Finance Video
Tony Hsieh, iconic Las Vegas tech entrepreneur, dies aged 46
Advertise With Us
© 2020 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research